hodgkin's%20lymphoma
HODGKIN'S LYMPHOMA

Hodgkin's lymphoma is a malignancy that arises from germinal center B cell.

Histologically, there is a presence of multinucleated giant cells in a mixed inflammatory background.

It is also known as Hodgkin's disease, Hodgkin lymphoma or Hodgkin disease.

It commonly affects individuals ages 15-30 years old and those 55 years old and above.

The key morphologic characteristics include presence of Reed-Sternberg cells and lymphocyte-predominant cells.

Introduction

  • Also known as Hodgkin’s disease, Hodgkin lymphoma, or Hodgkin disease
  • Commonly affects ages 15-30 years old, & individuals 55 years old & above
  • Key morphologic characteristics include presence of Reed-Sternberg cells & lymphocyte-predominant cells
  • Divided into 2 types: Classic Hodgkin's lymphoma (CHL) & nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL)

Definition

  • A malignancy involving the lymph nodes & the lymphatic system

Etiology

  • Viruses (eg Epstein-Barr virus)
  • Positive family history of hematopoietic malignancy & autoimmune/chronic inflammatory diseases
  • Positive family history of Hodgkin's lymphoma

Prognostic Factors

  • Presence of the following reduces the survival rate by 7-8%/year
    • Age >45 years old
    • Gender - males are at increased risk
    • Patients diagnosed with stage IV disease
    • Albumin level: <4 g/dL
    • Hemoglobin (Hgb) level: <10.5 g/dL
    • Leukocytosis [White blood cell (WBC) >15,000/mm3]
    • Lymphocytopenia [Lymphocyte count <8% of white blood cell (WBC) &/or <600/mm3]

Signs and Symptoms

  • Assess patient’s performance status based on the clinical presentation
  • Painless peripheral adenopathies (commonly within the cervical or supraclavicular areas)
  • Chest pain or pain within the mediastinum
  • Pain at a nodal site after drinking alcohol
  • Chronic pruritus
  • Systemic B symptoms
    • Fever (>38oC/100.4oF)
    • Night sweats
    • Weight loss (>10% of baseline)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
03 Mar 2016
The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.